Total Payments
$202,813
2024 Payments
$40,296
Companies
28
Transactions
366
Medicare Patients
15,752
Medicare Billing
$16.2M
Payment Breakdown by Category
Other$139,063 (68.6%)
Consulting$31,565 (15.6%)
Travel$18,606 (9.2%)
Food & Beverage$13,542 (6.7%)
Gifts$19.40 (0.0%)
Education$17.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113,577 | 30 | 56.0% |
| Consulting Fee | $31,565 | 14 | 15.6% |
| Honoraria | $25,459 | 11 | 12.6% |
| Travel and Lodging | $18,606 | 40 | 9.2% |
| Food and Beverage | $13,542 | 268 | 6.7% |
| Entertainment | $26.47 | 1 | 0.0% |
| Gift | $19.40 | 1 | 0.0% |
| Education | $17.19 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $116,451 | 107 | $0 (2024) |
| Alimera Sciences, Inc. | $38,145 | 68 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $21,956 | 36 | $0 (2024) |
| Allergan, Inc. | $9,851 | 50 | $0 (2021) |
| F. Hoffmann-La Roche AG | $5,130 | 4 | $0 (2024) |
| Genentech, Inc. | $3,155 | 6 | $0 (2024) |
| Glaukos Corporation | $2,679 | 2 | $0 (2024) |
| Astellas Pharma US Inc | $2,616 | 6 | $0 (2024) |
| ABBVIE INC. | $592.53 | 25 | $0 (2024) |
| Notal Vision, Inc. | $497.94 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,296 | 61 | Genentech USA, Inc. ($20,583) |
| 2023 | $27,038 | 55 | Genentech USA, Inc. ($23,361) |
| 2022 | $34,353 | 54 | Genentech USA, Inc. ($28,822) |
| 2021 | $4,784 | 29 | Alimera Sciences, Inc. ($4,180) |
| 2020 | $8,507 | 27 | Alimera Sciences, Inc. ($5,357) |
| 2019 | $29,340 | 56 | Genentech USA, Inc. ($16,724) |
| 2018 | $47,816 | 59 | Genentech USA, Inc. ($26,517) |
| 2017 | $10,677 | 25 | Alimera Sciences, Inc. ($6,911) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $147.40 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/17/2024 | ANI Pharmaceuticals, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $136.68 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/04/2024 | Glaukos Corporation | iStent Trabecular Micro-Bypass System Model iS3 (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Glaucoma | ||||||
| 12/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: EYE CARE | ||||||
| 11/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $7.75 | General |
| Category: EYE CARE | ||||||
| 11/14/2024 | Harrow Eye, LLC | IHEEZO (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: OPTOMETRY | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $31.88 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/07/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $98.93 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $27.47 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/28/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $35.60 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/21/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: EYE CARE | ||||||
| 10/20/2024 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $126.17 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | F. Hoffmann-La Roche AG | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $3,570.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | F. Hoffmann-La Roche AG | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $223.86 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | F. Hoffmann-La Roche AG | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $75.77 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $174.20 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/24/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 4,067 | 60,422 | $6.3M | $4.3M |
| 2022 | 23 | 3,864 | 20,911 | $5.9M | $4.1M |
| 2021 | 22 | 4,072 | 16,119 | $5.6M | $4.0M |
| 2020 | 20 | 3,749 | 15,338 | $5.3M | $3.8M |
Total Patients
15,752
Total Services
112,790
Medicare Billing
$16.2M
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 279 | 2,662 | $2.7M | $1.8M | 69.2% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 165 | 46,620 | $1.8M | $1.4M | 75.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 115 | 2,169 | $871,600 | $395,293 | 45.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 539 | 2,190 | $315,626 | $208,366 | 66.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,112 | 2,263 | $290,056 | $200,864 | 69.2% |
| 92134 | Imaging of retina | Office | 2023 | 1,195 | 3,509 | $148,188 | $102,111 | 68.9% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 21 | 259 | $53,095 | $41,081 | 77.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 229 | 236 | $32,740 | $24,130 | 73.7% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 21 | 22 | $25,212 | $19,649 | 77.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 136 | 136 | $20,846 | $14,717 | 70.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 18 | 19 | $17,100 | $12,812 | 74.9% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 11 | 12 | $14,304 | $10,948 | 76.5% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 12 | 12 | $14,006 | $10,104 | 72.1% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 12 | 24 | $8,412 | $6,122 | 72.8% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 13 | 13 | $6,950 | $5,316 | 76.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $6,290 | $4,542 | 72.2% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 21 | 22 | $11,660 | $4,201 | 36.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 19 | 48 | $4,080 | $2,442 | 59.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 32 | $2,993 | $2,257 | 75.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 18 | $2,410 | $1,516 | 62.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 29 | 37 | $1,998 | $1,359 | 68.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 11 | 12 | $1,110 | $863.28 | 77.8% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 12 | 14 | $924.00 | $473.78 | 51.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 56 | $224.00 | $43.33 | 19.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 300 | 3,238 | $3.2M | $2.3M | 72.8% |
About Dr. Vishak John, M.D
Dr. Vishak John, M.D is a Ophthalmology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1255515623.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vishak John, M.D has received a total of $202,813 in payments from pharmaceutical and medical device companies, with $40,296 received in 2024. These payments were reported across 366 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($113,577).
As a Medicare-enrolled provider, John has provided services to 15,752 Medicare beneficiaries, totaling 112,790 services with total Medicare billing of $16.2M. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Winston Salem, NC
- Active Since 12/20/2007
- Last Updated 09/26/2016
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255515623
Products in Payments
- Vabysmo (Drug) $46,768
- Lucentis (Biological) $46,373
- VABYSMO (Drug) $27,906
- ILUVIEN (Drug) $25,052
- EYLEA AFLIBERCEPT INJECTION (Biological) $19,698
- OZURDEX (Drug) $10,342
- Iluvien (Drug) $10,303
- Izervay (Drug) $2,564
- iStent Trabecular Micro-Bypass System Model iS3 (Device) $2,500
- EYLEA (Biological) $2,007
- Iluvien (Biological) $1,339
- SUSVIMO (Drug) $872.28
- Susvimo (Drug) $816.33
- YUTIQ (Drug) $324.44
- EYLEA HD (Biological) $251.58
- ForeseeHome (Device) $225.23
- KXL system (not refurbished) (Device) $178.50
- DEXYCU (Drug) $150.33
- STELLARIS PC (Device) $145.52
- Syfovre (Drug) $134.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Winston Salem
Dr. Rajiv Shah, Md, MD
Ophthalmology — Payments: $951,661
Ophthalmology $951,661
Keith Walter, Md, MD
Ophthalmology — Payments: $722,167
Ophthalmology $722,167
Charles Richards, Md, MD
Ophthalmology — Payments: $9,728
Ophthalmology $9,728
Margaret Greven, M.d, M.D
Ophthalmology — Payments: $7,794
Ophthalmology $7,794
Dr. Vickas Khemsara, Md, MD
Ophthalmology — Payments: $6,351
Ophthalmology $6,351
Akshay Mentreddy, Do, DO
Ophthalmology — Payments: $4,975
Ophthalmology $4,975